VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
XTNTXtant Medical Holdings, Inc.
$0.44$62M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksXTNTP/E History

XTNT logoXtant Medical Holdings, Inc. (XTNT) P/E Ratio History

Deep Value

Trading at 14.7x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2023–2026

Current P/E (TTM)
14.7x
-77% vs 5Y avg
5Y Avg P/E
64.7x
Median 63.0x
5Y Percentile
0th
Lower end of range
PEG Ratio
N/A
5-Year P/E Range
14.7x
Min23.3xMedian63.0xMax129.4x
TTM EPS$0.01
Price$0.44
Earnings Yield6.81%
EPS Growth (1Y)125.0%
EPS Growth (5Y)N/A

Loading P/E history...

P/E Ratio Analysis

As of June 22, 2026, Xtant Medical Holdings, Inc. (XTNT) trades at a price-to-earnings ratio of 14.7x, with a stock price of $0.44 and trailing twelve-month earnings per share of $0.01.

The current P/E is 77% below its 5-year average of 64.7x. Over the past five years, XTNT's P/E has ranged from a low of 23.3x to a high of 129.4x, placing the current valuation at the 0th percentile of its historical range.

Compared to the Healthcare sector median P/E of 22.1x, XTNT trades at a 34% discount to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.

Relative to the broader market, XTNT trades at a notable discount to the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our XTNT DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

XTNT Cross-Benchmark Valuation

How does the current P/E compare to sector peers and the broader market?

vs. Healthcare
14.7vs22.1
-34%
Below Sector
vs. S&P 500
14.7vs24.4
-40%
Below Market
PEG Analysis
N/A
P/E ÷ EPS Growth
Based on 125% EPS growth (1Y)

XTNT P/E vs Peers

Orthopedics, spine, and sports medicine peers sorted by market cap

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
OSPN logoOSPNOneSpan Inc.
$506M7.1Lowest-+30%
GMED logoGMEDGlobus Medical, Inc.
$11B20.20.65Best+423%Best
OSIS logoOSISOSI Systems, Inc.
$4B25.61.55+18%
ZBH logoZBHZimmer Biomet Holdings, Inc.
$17B24.8--20%
SYK logoSYKStryker Corporation
$118B36.62.46+8%
MDT logoMDTMedtronic plc
$102B22.0-+31%

Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.

XTNT Historical P/E Data (2023–2026)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterPeriod EndPriceTTM EPSP/E Ratiovs Avg
FY2026 Q1-$0.54$0.0143.0x-34%
FY2025 Q4Dec 31 2025$0.78$0.0323.3x-64%
FY2025 Q3-$0.65$0.0163.0x-3%
FY2023 Q3Sep 30 2023$1.10$0.01129.4x+100%

Average P/E for displayed period: 64.7x

Export Data
Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

3+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

XTNT — Frequently Asked Questions

Quick answers to the most common questions about buying XTNT stock.

What is XTNT's P/E ratio?

Xtant Medical Holdings, Inc. (XTNT) trailing twelve-month P/E ratio is 14.7x, based on TTM diluted EPS of $0.01. The 5-year average P/E is 64.7x and the historical range spans 23.3x to 129.4x.

Is XTNT stock overvalued or undervalued?

XTNT trades at 14.7x P/E, below its 5-year average of 64.7x. At the 0th percentile of its historical range (23.3x–129.4x), the stock is priced at a discount to its own history.

Is XTNT stock expensive?

No, XTNT is not expensive on a historical basis. The current P/E of 14.7x is below the 5-year average of 64.7x and sits at the 0th percentile of its valuation range.

What is XTNT's historical P/E range?

Over the past 5 years, XTNT's P/E ratio has ranged from 23.3x to 129.4x, with a median of 63.0x and an average of 64.7x. The current P/E of 14.7x places the stock at the 0th percentile of this range. Full historical data spans 2023–2026.

How does XTNT's P/E compare to the S&P 500?

XTNT trades at 14.7x P/E versus the S&P 500 median of 24.4x. The 40% discount to the market suggests lower growth expectations or perceived higher risk.

How does XTNT's valuation compare to Healthcare peers?

Xtant Medical Holdings, Inc. P/E of 14.7x compares to the Healthcare sector median of 22.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.

What is XTNT's PEG ratio?

XTNT PEG ratio is N/A, based on a P/E of 14.7x and EPS growth of 125.0%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.

What is XTNT's earnings yield?

XTNT earnings yield is 6.81%, the inverse of its 14.7x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.

XTNT P/E Ratio History (2023–2026)

Quarterly valuation multiple from closing price and trailing EPS

Current43.0x
Period Avg64.7x
Range23.3x - 129.4x
Change-67%
4 quartersSep 30, 2023 - Mar 31, 2026